Autolus Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Autolus Therapeutics
AUTL Stock  USD 1.37  0.06  4.20%   
Autolus Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Autolus Therapeutics' valuation are provided below:
Gross Profit
-135.4 M
Market Capitalization
364.6 M
Enterprise Value Revenue
1.5453
Revenue
51.1 M
Earnings Share
(0.80)
There are over one hundred nineteen available fundamental signals for Autolus Therapeutics, which can be analyzed over time and compared to other ratios. We recommend to validate Autolus Therapeutics' prevailing fundamental drivers against the all of the trends between 2010 and 2026. Market Cap is expected to rise to about 749.9 M this year. Enterprise Value is expected to rise to about 552.3 M this year

Autolus Therapeutics Total Revenue

12.22 Million

Check Autolus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Autolus Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 4.8 M, Interest Expense of 6.8 M or Selling General Administrative of 122.1 M, as well as many indicators such as Price To Sales Ratio of 64.73, Dividend Yield of 0.0 or PTB Ratio of 1.53. Autolus financial statements analysis is a perfect complement when working with Autolus Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Autolus Stock
Check out the analysis of Autolus Therapeutics Correlation against competitors.
For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.

Autolus Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets945.1 M900.1 M353.4 M
Slightly volatile
Other Current Liabilities63 M60 M24.6 M
Slightly volatile
Total Current Liabilities73.3 M69.9 M27.5 M
Slightly volatile
Total Stockholder Equity516 M491.4 M238.1 M
Slightly volatile
Net Tangible Assets213.2 M343.5 M230.5 M
Slightly volatile
Property Plant And Equipment Net126.8 M120.8 M45.1 M
Slightly volatile
Accounts Payable2 M1.8 M4.8 M
Slightly volatile
Cash207.9 M261.5 M194.5 M
Slightly volatile
Non Current Assets Total147.1 M140.1 M54 M
Slightly volatile
Cash And Short Term Investments710 M676.2 M269.6 M
Slightly volatile
Net Receivables58.2 M55.5 M17.8 M
Slightly volatile
Common Stock Shares Outstanding308.1 M293.4 M89.6 M
Slightly volatile
Liabilities And Stockholders Equity945.1 M900.1 M353.4 M
Slightly volatile
Other Current Assets13 M23.6 M10 M
Slightly volatile
Other Stockholder Equity1.9 B1.8 B610.1 M
Slightly volatile
Total Liabilities429.1 M408.7 M115.3 M
Slightly volatile
Total Current Assets798.1 M760.1 M299.4 M
Slightly volatile
Intangible Assets11.7 M11.1 M8.4 M
Very volatile
Common Stock13.1 K13.8 K18.2 K
Pretty Stable
Property Plant Equipment36.1 M67.2 M33.5 M
Slightly volatile
Short and Long Term Debt Total30.7 M60.5 M21.9 M
Slightly volatile
Other Liabilities152.2 M144.9 M48.4 M
Slightly volatile
Non Current Liabilities Total355.8 M338.9 M88.1 M
Slightly volatile
Capital Surpluse325.1 M575.6 M392.4 M
Slightly volatile
Property Plant And Equipment Gross168.7 M160.6 M59.2 M
Slightly volatile
Non Current Liabilities Other295.4 M281.3 M76.9 M
Slightly volatile
Net Invested Capital276.9 M491.4 M268.8 M
Slightly volatile
Preferred Stock Total Equity1.1 K1.1 K49.2 K
Slightly volatile
Net Working Capital724.7 M690.2 M316.9 M
Slightly volatile
Other Assets1.091.151.3 M
Slightly volatile
Common Stock Total Equity2.6 K2.7 K9.3 K
Very volatile
Capital Stock14.5 K13.8 K4.9 K
Slightly volatile
Capital Lease Obligations42.4 M60.5 M33.5 M
Slightly volatile
Short Term Debt4.3 M3.4 M3.2 M
Slightly volatile

Autolus Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization4.8 M8.9 M3.9 M
Slightly volatile
Selling General Administrative122.1 M116.2 M38 M
Slightly volatile
Total Revenue12.2 M11.6 M3.4 M
Slightly volatile
Other Operating Expenses303.7 M289.3 M127.7 M
Slightly volatile
Research Development190.9 M181.9 M76.9 M
Slightly volatile
Total Operating Expenses103 M127.1 M83.9 M
Slightly volatile
Interest Income39.1 M37.2 M8 M
Slightly volatile
Reconciled Depreciation5.9 M8.9 M4.3 M
Slightly volatile
Selling And Marketing Expenses877.6 K987.3 K1.1 M
Slightly volatile

Autolus Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation4.8 M8.9 M3.9 M
Slightly volatile
Capital Expenditures42 M40 M14.1 M
Slightly volatile
End Period Cash Flow208 M263.1 M194.6 M
Slightly volatile
Stock Based Compensation12.6 M17.8 M10 M
Slightly volatile
Begin Period Cash Flow193.6 M276.4 M161.3 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio64.7368.141.3 K
Slightly volatile
PTB Ratio1.531.617.33
Slightly volatile
Days Sales Outstanding2.3 K2 K1.8 K
Slightly volatile
Book Value Per Share1.831.933.2976
Very volatile
Stock Based Compensation To Revenue1.311.384.0999
Pretty Stable
Capex To Depreciation3.325.192.5654
Slightly volatile
PB Ratio1.531.617.33
Slightly volatile
Inventory Turnover22.3830.6727.4471
Slightly volatile
Days Of Inventory On Hand15.0712.3213.8736
Slightly volatile
Payables Turnover67.6864.4636.227
Slightly volatile
Sales General And Administrative To Revenue21.7331.6631.1243
Slightly volatile
Research And Ddevelopement To Revenue13.3614.0630.6353
Pretty Stable
Capex To Revenue5.743.965.9262
Slightly volatile
Cash Per Share4.252.653.1408
Slightly volatile
Days Payables Outstanding5.575.86433
Slightly volatile
Income Quality0.620.840.6951
Slightly volatile
Intangibles To Total Assets0.01730.01820.1594
Slightly volatile
Net Debt To EBITDA0.820.862.0428
Slightly volatile
Current Ratio12.7112.5110.255
Pretty Stable
Tangible Book Value Per Share1.781.873.0109
Pretty Stable
Receivables Turnover0.180.191.6843
Pretty Stable
Shareholders Equity Per Share1.831.933.2976
Very volatile
Debt To Equity0.110.12320.0953
Slightly volatile
Capex Per Share0.20.160.1674
Slightly volatile
Revenue Per Share0.05360.04560.0401
Slightly volatile
Interest Debt Per Share0.340.220.2971
Slightly volatile
Debt To Assets0.06260.06050.0554
Slightly volatile
Operating Cycle2.3 K2 K1.8 K
Slightly volatile
Price Book Value Ratio1.531.617.33
Slightly volatile
Days Of Payables Outstanding5.575.86433
Slightly volatile
Ebt Per Ebit0.70.820.8639
Pretty Stable
Company Equity Multiplier1.21.651.3798
Slightly volatile
Long Term Debt To Capitalization0.120.13050.0684
Slightly volatile
Total Debt To Capitalization0.0880.09870.0766
Slightly volatile
Debt Equity Ratio0.110.12320.0953
Slightly volatile
Quick Ratio12.6812.4310.2341
Pretty Stable
Net Income Per E B T0.760.910.941
Very volatile
Cash Ratio4.094.38.0508
Pretty Stable
Days Of Inventory Outstanding15.0712.3213.8736
Slightly volatile
Days Of Sales Outstanding2.3 K2 K1.8 K
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.291.341.1993
Pretty Stable
Price To Book Ratio1.531.617.33
Slightly volatile
Fixed Asset Turnover0.130.110.1114
Pretty Stable
Debt Ratio0.06260.06050.0554
Slightly volatile
Price Sales Ratio64.7368.141.3 K
Slightly volatile
Asset Turnover0.01160.01490.0093
Pretty Stable
Price Fair Value1.531.617.33
Slightly volatile

Autolus Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap749.9 M689.6 M822.7 M
Slightly volatile
Enterprise Value552.3 M488.6 M636.2 M
Slightly volatile

Autolus Fundamental Market Drivers

Autolus Upcoming Events

5th of March 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
5th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Autolus Therapeutics Financial Statements

Autolus Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how Autolus Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-5.9 M-5.6 M
Total Revenue11.6 M12.2 M
Cost Of Revenue162.2 M170.3 M
Stock Based Compensation To Revenue 1.38  1.31 
Sales General And Administrative To Revenue 31.66  21.73 
Research And Ddevelopement To Revenue 14.06  13.36 
Capex To Revenue 3.96  5.74 
Revenue Per Share 0.05  0.05 
Ebit Per Revenue(27.43)(28.81)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Autolus Therapeutics is a strong investment it is important to analyze Autolus Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Autolus Therapeutics' future performance. For an informed investment choice regarding Autolus Stock, refer to the following important reports:
How To Invest In Autolus
Details
Is Autolus Stock a good investment?
Details
What is Autolus Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Autolus Therapeutics Correlation against competitors.
For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.
You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Autolus Therapeutics. If investors know Autolus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Autolus Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
(0.80)
Revenue Per Share
0.192
Quarterly Revenue Growth
(0.11)
Return On Assets
(0.23)
Return On Equity
(0.61)
The market value of Autolus Therapeutics is measured differently than its book value, which is the value of Autolus that is recorded on the company's balance sheet. Investors also form their own opinion of Autolus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Autolus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Autolus Therapeutics' market value can be influenced by many factors that don't directly affect Autolus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Understanding that Autolus Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Autolus Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Autolus Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY